INTRODUCTION Strictureplasty, introduced in 1978, has been suggested as an alternative to small bowel resection for cases of intestinal obstruction involving multiple segments, such as in Crohn's disease. Despite research supporting the operation, little is known about outcomes after strictureplasty. Specifically, 30-day readmission and reoperation rates, which are widely recognized as surrogates for quality of surgical care have not been studied for this procedure. We sought to study the rate of, as well as factors associated with 30-day outcomes, including readmission and reoperation. METHODS We used the National Surgical Quality Improvement Program (NSQIP) participant user files (PUF) for the years 2012-2020. Primary Current Procedural Terminology (CPT) code "44615" was used to identify patients undergoing strictureplasty as their principal procedure. The outcomes of interest included related thirty-day readmissions and reoperations, non-routine discharge, and prolonged length of stay (LOS). Multivariable analyses were performed to identify factors associated with each outcome. RESULTS A total of 535 patients were identified with mean age 44.14 years (SD= 15.74). 52.5% were female. Thirty-day related readmission and reoperation rates were 9% (n=48) and 6% (n=32) respectively. Average LOS was 8.16 days (SD= 6.9). Non-routine discharge rate was4.2% (n=21). On multivariable logistic regression, factors associated with 30-day readmissions included longer operative time (OR 1.00, 95% CI 1.00-1.01, p=0.0008) and any surgical site infection (SSI) (OR 6.4, 95% CI 2.89-14.2, p<0.001). Increased LOS (OR 1.7, 95%CI 1.03-1.11, p=0.0009) and SSI (OR 28.1, 95%CI 10.44-75.47, p<0.001) were associated with 30-day related reoperation. Predictors of non-routine discharge included older age (65+ vs 18-40: OR 30.72, 95%CI 3.14-300.74, p=0.003) and longer LOS (OR 1.09, 95%CI 1.03-1.14, 0.0009). Factors associated with increased odds of prolonged LOS included higher ASA class (OR 3.29, 95%CI 2.10-5.14, p<0.001), longer operative time (1.00, 95%CI 1.00-1.01, p=0.0008) and SSI (OR 3.05, 95%CI 1.57-5.90, p=0.0009). Factors associated with lower odds of prolonged LOS included male sex (OR 0.56, 96%CI 0.36-0.88, p=0.011) and preoperative steroid use (OR 0.62, 95%CI 0.38-0.99, p=0.04). CONCLUSION Our analyses indicate that among patients undergoing strictureplasty, longer operative time, wound complications, and longer length of stay are associated with increased odds of readmission and reoperation within 30 days. These findings may be important for hospitals, providers, payors, and other stakeholders in further refining standards of quality of care for patients undergoing strictureplasty.

The authors have declared no competing interest.

This study did not receive any funding.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Access to the data was granted after registration. Individuals requesting the data in the ACS NSQIP Participant Use Data File ("PUF") represent a ACS NSQIP Participating Hospital, Robert Packer Hospital ( See https://www.facs.org/institute/12230/) The Institutional Review Board (IRB) of the Guthrie Clinic provides ethical oversight for the collection of the original data. The IRB office reviewed the data use agreements completed by individuals accessing the data. Per institutional policy, approval by the IRB is not required for use of a limited data set. https://guthrie-system.policystat.com/policy/10906808/latest

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced are available online at ACS website which is provided as NSQIP data set.